Literature DB >> 32967963

Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.

Anna Godi1, Dolcibella Boampong1, Busayo Elegunde1, Kavita Panwar1, Maxime Fleury2, Shaowei Li3, Qinjian Zhao3, Ningshao Xia3, Neil D Christensen4, Simon Beddows5.   

Abstract

Human papillomavirus (HPV) is the causative agent of cervical and other epithelial cancers. Naturally occurring variants of HPV have been classified into lineages and sublineages based on their whole-genome sequences, but little is known about the impact of this diversity on the structure and function of viral gene products. The HPV capsid is an icosahedral lattice comprising 72 pentamers of the major capsid protein (L1) and the associated minor capsid protein (L2). We investigated the potential impact of this genome variation on the capsid antigenicity of lineage and sublineage variants of seven vaccine-relevant, oncogenic HPV genotypes by using a large panel of monoclonal antibodies (MAbs) raised against the L1 proteins of lineage A antigens. Each genotype had at least one variant that displayed a ≥4-fold reduced neutralizing antibody sensitivity against at least one MAb, demonstrating that naturally occurring variation can affect one or more functional antigenic determinants on the HPV capsid. For HPV16, HPV18, HPV31, and HPV45, the overall impact was of a low magnitude. For HPV33 (sublineages A2 and A3 and lineages B and C), HPV52 (lineage D), and HPV58 (lineage C), however, variant residues in the indicated lineages and sublineages reduced their sensitivity to neutralization by all MAbs by up to 1,000-fold, suggesting the presence of key antigenic determinants on the surface of these capsids. These determinants were resolved further by site-directed mutagenesis. These data improve our understanding of the impact of naturally occurring variation on the antigenicity of the HPV capsid of vaccine-relevant oncogenic HPV genotypes.IMPORTANCE Human papillomavirus (HPV) is the causative agent of cervical and some other epithelial cancers. HPV vaccines generate functional (neutralizing) antibodies that target the virus particles (or capsids) of the most common HPV cancer-causing genotypes. Each genotype comprises variant forms that have arisen over millennia and which include changes within the capsid proteins. In this study, we explored the potential for these naturally occurring variant capsids to impact recognition by neutralizing monoclonal antibodies. All genotypes included at least one variant form that exhibited reduced recognition by at least one antibody, with some genotypes affected more than others. These data highlight the impact of naturally occurring variation on the structure of the HPV capsid proteins of vaccine-relevant oncogenic HPV genotypes. © Crown copyright 2020.

Entities:  

Keywords:  antigenicity; human papillomavirus; lineage; monoclonal antibodies; neutralization; variant

Mesh:

Substances:

Year:  2020        PMID: 32967963      PMCID: PMC7925199          DOI: 10.1128/JVI.01236-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.

Authors:  Raeda Z Rizk; Neil D Christensen; Kristina M Michael; Martin Müller; Peter Sehr; Tim Waterboer; Michael Pawlita
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

2.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

3.  Human papillomavirus 45 genetic variation and cervical cancer risk worldwide.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

4.  Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.

Authors:  Anna Godi; Alessandra Facchetti; Sara L Bissett; Clementina Cocuzza; Elizabeth Miller; Simon Beddows
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

5.  Monoclonal antibodies to the haemagglutinin HA1 subunit of the pandemic influenza A/H1N1 2009 virus and potential application to serodiagnosis.

Authors:  Dhanraj Samuel; Lenesha Warrener; Katja Hoschler
Journal:  J Med Virol       Date:  2011-04       Impact factor: 2.327

Review 6.  Understanding and learning from the success of prophylactic human papillomavirus vaccines.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Nat Rev Microbiol       Date:  2012-09-10       Impact factor: 60.633

7.  The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Hyunwook Lee; Robert E Ashley; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

8.  Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide.

Authors:  Alyce A Chen; Tarik Gheit; Silvia Franceschi; Massimo Tommasino; Gary M Clifford
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

9.  Explanations for the high potency of HPV prophylactic vaccines.

Authors:  John Schiller; Doug Lowy
Journal:  Vaccine       Date:  2018-01-08       Impact factor: 3.641

10.  Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.

Authors:  Anna Godi; Troy J Kemp; Ligia A Pinto; Simon Beddows
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

View more
  2 in total

1.  Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay.

Authors:  Kavita Panwar; Anna Godi; Clementina E Cocuzza; Nick Andrews; Jo Southern; Paul Turner; Elizabeth Miller; Simon Beddows
Journal:  MethodsX       Date:  2022-06-25

2.  Prevalence and distribution of human papillomavirus (HPV) in Luoyang city of Henan province during 2015-2021 and the genetic variability of HPV16 and 52.

Authors:  Xiuli Wang; Shuizhong Han; Xingwei Li; Xiaochuan Wang; Shan Wang; Li Ma
Journal:  Virol J       Date:  2022-03-04       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.